Edit

Sofinnova Investments

https://www.sofinnova.com
Last activity: 16.07.2024
Active
Invests in categories: MedTechDevelopmentDrugBioTechHealthTechProductTechnologyPlatformCareInformation
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
News
317
Portfolio
92
Mentions
85
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Series A; Series C; Series E

Portfolio 92

DateNameWebsiteTotal RaisedLocation
25.10.2023Aiolos Bioaiolosbio.com$245MUnited Sta...
24.09.2023Rapport Th...rapportrx.com$150MUnited Sta...
24.09.2023Star Thera...star-therapeutics.com$90MUnited Sta...
16.06.2023Alkeus Pha...alkeuspharma.com$150MUnited Sta...
27.04.2023Antiva Bio...antivabio.com$137MUnited Sta...
14.04.2023ArriVent B...arrivent.com$415MUnited Sta...
02.10.2022RayzeBiorayzebio.com$373.53MUnited Sta...
27.03.2021Gyroscope ...gyroscopetx.com$423.34MUnited Kin...
17.12.2020Atsena The...atsenatx.com$55MUnited Sta...
08.11.2020Vera Thera...veratx.com$80MUnited Sta...
Show more

News 317

DateTitleDescription
11.01.2024Jim Healy Shares Perspective on What's Driving M&A Optimism for 2024 with WSJ-
10.01.2024Alkeus Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression-
09.01.2024GSK Enters Agreement to Acquire Aiolos Bio-
04.01.2024OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients-
22.12.2023Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics-
20.12.2023Ascendis Announces Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide)-
14.12.2023Karuna Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia-
13.12.2023BioSpace Reporter Tyler Patchen Spoke with Jakob Dupont and Other Industry Professionals for Advice on How to Optimize Time at JPM Healthcare Conference-
29.11.2023Karuna Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia-
20.11.2023Aerovate Announces Simultaneous Completion of Enrollment in Phase 2b and Enrollment of First Patient into Phase 3 in IMPAHCT Trial for Pulmonary Arterial Hypertension-
Show more

Mentions in press and media 85

DateTitleDescription
16.07.2024EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing roundEQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round Tue, Jul 16, 2024 09:15 CET Report this content EQT Life Sciences has invested in Asceneuron’s oversubscr...
28.05.2024Asahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of CalliditasAsahi Kasei announces a recommended public cash offer to the shareholders and ADS holders of Calliditas Tue, May 28, 2024 08:15 CET Report this content THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER T...
12.03.2024Nvidia стала делать ставку на все технологии, связанные с ИИ. За год компания инвестировала в 30 стартапов $1,55 млрд...Последний год для производителя чипов Nvidia стал поворотным, поскольку он превзошел все ожидания и к концу февраля достиг рыночной капитализации более $2 трлн. Это сделало компанию крупнейшей по рыночной капитализации после Microsoft и App...
11.03.2024It's not just chips. Nvidia is betting on other tech that could be impacted by AI.Tech It's not just chips. Nvidia is betting on other tech that could be impacted by AI. Lloyd Lee 2024-03-11T03:42:26Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An envelope. It indicate...
27.10.2023Sofinnova Partners raises $200m for maiden digital medicine fund-
01.04.2020Sofinnova Investments Adds Jonathan Leff as Executive PartnerSofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner. With more than 25 years of clinical development experience in the biot...
31.03.2020Sofinnova Investments Promotes TwoSofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, promoted Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner. Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, ha...
18.03.2020Sofinnova Investments Adds Jonathan Leff as Executive PartnerSofinnova Investments, a clinical stage biopharmaceutical investment firm, added Jonathan Leff, M.D. to the investment team as an Executive Partner. With more than 25 years of clinical development experience in the biotechnology and pharmac...
17.10.2019Sofinnova Partners raises $370.3 million for its early-stage healthcare fund to invest in healthtech and life sciences startupsInvestments in healthcare and Life Sciences startups continue to soar. Now, the sector is boosted by today’s announcement from Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in L...
22.04.2019Sofinnova Investments Adds Maha Katabi as a PartnerMaha Katabi, PhD. Sofinnova Investments, a Menlo Park, Calif.-based clinical stage biopharmaceutical investment firm, added Maha Katabi, PhD. to the investment team as a Partner. Maha Katabi, PhD., is an experienced investor in biopharma co...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In